Dr. Elkhosht announces an increase in the impact factor of the Journal of the Egyptian National Cancer Institute (JENCI), according to Clarivate Analytics

CU President: The citation index for 2023 increased by 67% compared to the 2022 index.

Dr. Elkhosht: The successes achieved by JENCI are part of the series of achievements of CU journals internationally in a number of prominent specializations

Dr. Elkhosht: JENCI is published electronically in cooperation with the international publishing house Springer Nature, which gives it many advantages

Dr. Elkhosht: The high impact factor and citation rates ensure JENCI’s prominence among international medical science journals listed by prominent classification organizations in the field of oncology.

Dr. Mohamed Abdel Moati: The acceptance rate for research in JENCI has been only 14% since 2021 and has decreased to 7% in 2024.

Dr. Mohamed Abdel Moati: Diversity of researchers by nationality in JENCI and foreign research have increased at a rate of 83% since 2021.

Dr. Tarek Khairy: JENCI publishes research on the latest innovations in all oncology sciences, such as basic, applied, and clinical cancer research



Dr. Mohamed Othman Elkhosht, President of Cairo University, has announced an increase in the impact factor of CU’s Journal of the Egyptian National Cancer Institute (JENCI) within one year from 1.8 in 2022 to 2.1 in 2023, according to Clarivate Analytics, in addition to achieving an increase in the citation index from 2.2 in 2022 to 3.5 in 2023, an increase of 67%.

According to Dr. Elkhosht, JENCI’s success in achieving impact factors and citation rates guarantees it a place among the medical sciences journals listed globally by the world’s highest oncology journal classification institutions, indicating that JENCI’s achievement forms part of a string of successes for CU journals internationally in a number of important specializations.

JENCI, according to Dr. Elkhosht, is the official magazine of the National Cancer Institute, and was first issued in 1982. The magazine is published electronically in cooperation with the international publishing house Springer Nature, which gives the magazine many advantages, including membership in the global COPE (Committee on Publication Ethics) foundation, and uses the most accurate plagiarism-detection software, iThenticate, as well as other features.

Dr. Elkhosht confirmed that the journal is listed in a large number of international databases, including Emerging Sources Citation Index (Web of Science), SCOPUS, Clarivate, Medline, DOAJ, EBSCO Discovery Service, and EMBAS.

For his part, Dr. Mohamed Abdel Moati, Dean of the National Cancer Institute, explained that the support of the university administration has contributed to raising all of the journal’s international classification, noting the demand among researchers to publish in JENCI, as evidenced by a 10% increase in new submissions in 2023 over 2022.

Dr. Abdel Moati confirmed that the rate of acceptance of research in the journal has been only 14% since 2021 and has decreased to 7% in 2024, which means a high rate of rejection by the journal’s editorial board beginning in 2021. This indicates compliance with international standards for acceptance in JENCI. The journal follows a double-blind peer-review system, with no less than 3 reviewers, two of whom are specialists in the field and the third a statistician.

Dr. Abdel Moati pointed out that the journal receives papers from all over the world, with a proven increase in the diversity of researcher nationalities at JENCI, in addition to an increase in foreign research since the year 2021 at a rate of 83%.

Dr. Tariq Khairy, Vice Dean of the Oncology Institute for Postgraduate Studies and Research, added that JENCI publishes research on the latest innovations in all oncology sciences, such as basic, applied, and clinical cancer research, with priority given to key topics such as topical and systemic targeted anti-cancer therapy, with special attention to applied cancer research from developing countries. JENCI also publishes papers on experimental oncology, early cancer detection and key emerging areas in diagnostic medicine such as molecular pathology, bioinformatics and biotechnologies.

Dr. Khairy confirmed that JENCI has been published on a regular monthly basis since its partnership with Springer Nature and publishes an average of 4 papers per month, noting the strict scientific and ethical standards followed by the editor-in-chief of the magazine, Dr. Hussein Khaled, former Minister of Higher Education and Professor of Oncology at the National Cancer Institute. The journals editorial director, Dr. Mohamed Sayed Ahmed, professor of pharmacology and experimental cancer treatment at the National Cancer Institute, has contributed to JENCI’s achievement of outstanding progress in all indicators issued by international scientific databases, which has led to an increase in researcher interest in publishing with JENCI.

Latest News